RxDoctor Payments Data

Carlos Valentin, MD

Family Medicine · Wallingford, CTNPI 1366454357

Payments from drug & device makers

$493in general payments, 2019–2025

Across 24 payments — averaging $20.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Merck$202
  • Johnson & Johnson$190
  • Lilly USA, LLC$35
  • Boehringer Ingelheim$19
  • Sanofi Pasteur Inc.$17
  • AstraZeneca$16
  • plus $15 from 1 others

What the payments were for

  • Food & beverage$493100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$493 in reported general payments places this provider in the 60th percentile of 588 family medicine providers in Connecticut.

See all family medicine providers in Connecticut

Medicare billing

Part B allowed, 2024
$41,397
Medicare patients
103
Services billed
916

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin132$192,856
OzempicSemaglutide111$139,903
JanuviaSitagliptin Phosphate56$92,963
EliquisApixaban53$43,815
TradjentaLinagliptin33$31,037
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog24$25,334
FarxigaDapagliflozin Propanediol14$20,849
MounjaroTirzepatide18$19,546
LinzessLinaclotide13$12,581
Tresiba Flextouch U-100Insulin Degludec13$11,008
VascepaIcosapent Ethyl15$8,445
Lantus SolostarInsulin Glargine,hum.Rec.Anlog38$7,572
Levemir FlexpenInsulin Detemir12$7,351
Insulin Lispro Kwikpen U-100Insulin Lispro24$6,671
Qvar RedihalerBeclomethasone Dipropionate19$5,824

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta$19$223,892165 claims
MerckJanuvia$202$92,96356 claims
AstraZenecaFarxiga$16$20,84914 claims
Lilly USA, LLCMounjaro$35$19,54618 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 588 family medicine providers in Connecticut.

Other family medicine in Wallingford

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →